Bard Announces Second Quarter Results

Before you go, we thought you'd like these...
Before you go close icon

Bard Announces Second Quarter Results

MURRAY HILL, N.J.--(BUSINESS WIRE)-- C. R. Bard, Inc. (NYS: BCR) today reported 2013 second quarter financial results. Second quarter 2013 net sales were $759.9 million, an increase of 2 percent over the prior-year period on a reported basis. Excluding the impact of foreign exchange, second quarter 2013 net sales increased 3 percent over the prior-year period.

For the second quarter 2013, net sales in the U.S. were $497.6 million, an increase of 2 percent over the prior-year period. Net sales outside the U.S. were $262.3 million, an increase of 4 percent over the prior-year period on both a reported and constant currency basis.


For the second quarter 2013, net loss was ($161.6 million) and diluted loss per share was ($2.03), reflecting a net charge for estimated costs related to product liability matters. Adjusting for this charge and other items that affect the comparability of results between periods as detailed in the tables below, second quarter 2013 net income was $117.2 million and diluted earnings per share were $1.42, a decrease of 17 percent and 12 percent, respectively, as compared to second quarter 2012 results.

Timothy M. Ring, chairman and chief executive officer, commented, "Our operating results this quarter exceeded our expectations. We continue to focus on the execution of our investment plan, which we believe will shift the mix of our portfolio to faster growing products and geographies and contribute to long-term sustainable leadership positions in our markets."

C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill, NJ, is a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products.

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current expectations, the accuracy of which is necessarily subject to risks and uncertainties. These statements are not historical in nature and use words such as "anticipate," "estimate," "expect," "project," "intend," "forecast," "plan," "believe," and other words of similar meaning in connection with any discussion of future operating or financial performance. Many factors may cause actual results to differ materially from anticipated results including product developments, sales efforts, income tax matters, the outcomes of contingencies such as legal proceedings, and other economic, business, competitive and regulatory factors. The company undertakes no obligation to update its forward-looking statements. Please refer to the Cautionary Statement Regarding Forward-Looking Information in our March 31, 2013 Form 10-Q for more detailed information about these and other factors that may cause actual results to differ materially from those expressed or implied.

C. R. Bard, Inc.
Consolidated Statements of Operations
(dollars and shares in thousands except per share amounts, unaudited)
 
 Quarter Ended Six Months Ended
June 30,June 30,

2013

 

2012

2013

 

2012

 
Net sales$759,900$742,600$1,500,200$1,472,600
Costs and expenses
Cost of goods sold296,600285,700591,900565,100
Marketing, selling and administrative expense226,300205,400442,700407,700
Research and development expense66,10050,100125,40098,300
Interest expense11,1009,70022,50019,200
Other (income) expense, net 295,700  6,200  326,000  5,400 
 
Total costs and expenses 895,800  557,100  1,508,500  1,095,700 
(Loss) income from operations before income taxes (135,900) 185,500  (8,300) 376,900 
 
Income tax provision 25,700  51,600  62,600  104,300 
 
Net (loss) income$(161,600)$133,900 $(70,900)$272,600 
 
Basic (loss) earnings per share available to common shareholders$(2.03)$1.56 $(0.88)$3.18 
 
Diluted (loss) earnings per share available to common shareholders$(2.03)$1.54 $(0.88)$3.14 
 
Wt. avg. common shares outstanding - basic79,80083,90080,60084,000
 
Wt. avg. common and common equivalent shares outstanding - diluted79,80085,10080,60085,100
 
Product Group Summary of Net Sales
(dollars in thousands, unaudited)
  
 

Quarter Ended June 30,

Six Months Ended June 30,

   Constant  Constant
20132012ChangeCurrency20132012ChangeCurrency
Vascular$212,200$221,300-4%-4%$415,400$430,500-4%-4%
Urology191,700188,8002%2%380,500373,9002%2%
Oncology214,100199,1008%8%421,200398,0006%6%
Surgical Specialties120,000111,4008%8%240,300226,1006%6%
Other 21,900  22,000 -- 42,800  44,100 -3%-3%
 
Net sales$759,900 $742,600 2%$1,500,200 $1,472,600 2%
 
Foreign exchange impact  (1,400)  300
Constant Currency$759,900 $741,200 3%$1,500,200 $1,472,900 2%
 
Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners

More to Explore
Thu, Feb 23
Set Your Location
City, State, or Zip
Reconciliation of (Loss) Earnings
(dollars in millions except per share amounts, unaudited)
 
 Quarter Ended June 30, 2013
      Diluted
(Loss) Earnings
Marketing,per Share
Cost ofSelling andResearch &OtherAvailable
GoodsAdministrativeDevelopment(Income)IncomeNet (Loss)to Common
SoldExpenseExpenseExpense, NetTaxesIncomeShareholders (1)
 
GAAP Basis$296.6$226.3$66.1$295.7$25.7$(161.6)$(2.03)

Items that affect comparability of results between periods:

Acquisition-related items(0.2)(0.8)(0.9)-0.21.7
Asset impairments(0.6)--(2.6)0.23.0
Restructuring---1.4(0.4)(1.0)
Litigation charges, net -  -  -  (292.4) 17.3  275.1  
Total(0.8)(0.8)(0.9)(293.6)17.3278.83.37
       
Adjusted Basis$295.8 $225.5 $65.2 $2.1 $43.0 $117.2 $1.42 
 
 
Quarter Ended June 30, 2012
Diluted
Earnings
Marketing,per Share
Cost ofSelling andResearch &OtherAvailable
GoodsAdministrativeDevelopment(Income)IncomeNetto Common
SoldExpenseExpenseExpense, NetTaxesIncomeShareholders
 
GAAP Basis$285.7$205.4$50.1$6.2$51.6$133.9$1.54

Items that affect comparability of results between periods:

Acquisition-related items(0.1)(0.1)(0.4)(0.2)-0.8
Asset impairments---(9.0)3.25.8
Restructuring---1.6(0.5)(1.1)
Tax Item -  -  -  -  (1.1) 1.1  
Total(0.1)(0.1)